
|Articles|January 12, 2021
Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients
Author(s)OT Staff Reports
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix randomizes first patient in HELIOS-3
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
4
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
5


















































.png)


